Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822545 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL17101486 | 0.81 | OPRL1 (0.46) | SMN1; SMN2ALDH1A1DDB1CRBNHSD17B10 | |
| SCHEMBL11365386 | 0.80 | GBA1 (0.41) | ALDH1A1TSHRDDB1CRBNHSD17B10 | |
| SCHEMBL23289886 | 0.75 | TRPV6 (0.35) | SMN1; SMN2ALDH1A1TSHRL3MBTL1OPRM1 | |
| SCHEMBL17101275 | 0.71 | CHRM1 (0.41) | ALDH1A1OPRD1KDM4E | |
| SCHEMBL11368873 | 0.70 | — | — | |
| SCHEMBL17101519 | 0.67 | — | — | |
| SCHEMBL11364638 | 0.67 | OPRD1 (0.40) | ALDH1A1HSD17B10OPRM1OPRD1OPRK1 | |
| SCHEMBL9771809 | 0.66 | KMT2A (0.40) | SMN1; SMN2HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL4458406 | 0.66 | MEN1 (0.36) | HPGDALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| CN-110903306-B | Muscarinic receptor agonists | 赫普泰雅治疗有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| EP-3271358-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| EP-3119396-A1 | MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2017-01-25 | — | — | EP | disclosed |
| WO-2016147011-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016147011-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 3168/4885HPGD 1939/4885RAB9A 1294/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 3211/4885HPGD 1929/4885RAB9A 1326/4885 |
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 3211/4885HPGD 1929/4885RAB9A 1326/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 3211/4885HPGD 1929/4885RAB9A 1326/4885 |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | SMN1; SMN2 3854/4885HPGD 2238/4885RAB9A 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.